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SUMMARY
Introduction: Coeliac disease (CD) is the most common Th1-mediated enteropathy, frequently 
associated with other immune-mediated disorders (IMD). Aims: to evaluate: 1) the prevalence of 
IMD at the time of and after CD diagnosis; 2) a possible change in immune response to gluten 
free diet (GFD); 3) the potential role of GFD in reducing and/or preventing IMD in CD. 
Methods: prospective study including all consecutive adult CD patients who underwent 
investigations for Th1-Th17/Th2-IMD at the time of CD diagnosis and after a 5-year follow-up 
period. Results: 1255 CD were enrolled. Of these, 257 patients (20.5%) showed IMD at the time 
of CD diagnosis, with 58.4% presenting a Th1/Th17-IMD. After a 5-year follow-up period, 682 
patients (54.3%) showed new IMD despite GFD. Of these, 57.3% presented a Th1/Th17-IMD 
and 42.7% a Th2-IMD (p=0.8). When compared the prevalence of each type of IMD before and 
after CD diagnosis, we did not identify any significant “switch” from Th1/Th17- to Th2-IMD or 
vice versa. The number of patients with Th1/Th17- and/or Th2-IMD increased during the GFD 
period (20.5% vs 54.3%; p<0.01; OR 1.9). Conclusions: The prevalence of IMD at the time of 
CD diagnosis is high and it seems to increase in the follow-up period despite GFD. 
KEY WORDS: Coeliac disease, gluten, autoimmunity, immuno-mediated diseases, Th1, Th2, Th17
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INTRODUCTION
Coeliac disease (CD) is the most common enteropathy in Western genetically susceptible 
subjects (HLA DQ2/DQ8) [1] mediated by a T helper cell type (Th) 1 immune response to 
gluten, a complex of water insoluble proteins from wheat, barley and rye [2].  
Indeed, as a chronic autoimmune disorder, both innate and adaptive immune responses are 
involved in the pathogenesis of CD [3].
Some studies have shown how the translocation of α2-gliadin-33mer may depend on an apical-
basal transcytosis stimulated by INF-γ, a cytokine involved in immunopathogenesis of CD [4]. 
Once it has reached the lamina propria, the gliadin would react with the tissue transglutaminase 
(tTG) – i.e. the enzyme catalyzing glutamine’s deamidation– thus creating a transglutaminase-
gliadin deamidated complex [5]. The deamidated peptide would be picked up by HLA DQ2 or 
DQ8 molecules on the surface of antigen-presenting cells (APC), and would be "presented" to 
the CD4 + T helper 1 (Th1). These Th1-cells would produce high levels of pro-inflammatory 
cytokines (IL2, IL6, INFγ, TNF), which could promote an increased cytotoxicity of 
intraepithelial lymphocytes (IELs) and natural killer (NK) T cells, causing apoptosis of 
enterocytes and the production of Th2 cytokines activating B cells and favoring the 
differentiation of plasma cells, hence resulting in the release of antibodies: anti-gliadin and anti-
transglutaminase [6 – 9].
Despite this pathogenesis, it seems that both Th1/Th17- and Th2-mediated diseases may co-exist 
in cases of CD [10]. It is well known that CD patients show a particular tendency for multiple 
autoimmune and/or allergic and/or immuno-mediated disorders (IMD) over their lifetime [11-
12], which supports this possibility. 
To date, only hypotheses exist to explain the observed split in the association between the type of 
T lymphocyte-mediated reaction and CD. CD is frequently associated to other Th1/Th17-IMD 
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[13-15], such as type 1 diabetes mellitus [16], autoimmune thyroiditis [17], rheumatoid arthritis 
[18], psoriasis [19], multiple sclerosis [20]. More recently, several studies have also shown an 
association between CD and some Th2-mediated disorders [15]: allergies and asthma, eczema, 
rhinitis [21], urticaria [22], Grave’s disease [17], Sjogren syndrome [23], lichen planus [24], 
systemic lupus erythematosus [25]. 
To date, a gluten free diet (GFD) is considered the only treatment for CD. Numerous papers have 
investigated the effects of CD therapy on the incidence and prognosis of coexisting or 
subsequent IMD but thus far they have reported contradictory results [26-35]. The aims of our 
study were: 1) to establish the prevalence of IMD at the time and after CD diagnosis in a large 
sample of adult individuals; 2) to identify any possible changes in immune response after 
commencement of GFD, in particular with regard to shifts from Th1/Th17- to Th2-immune 
response or vice versa; and 3) to investigate the potential role of GFD in reducing and/or 
preventing IMD in adult CD patients.
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METHODS
Between September 2011 and February 2015 we carried out a prospective study including all 
consecutive adult CD patients (age > 18 years) followed up at our Gastrointestinal Unit (Tertiary 
Centre for Food Intolerance and CD, “Federico II” University, Naples, Italy). In accordance with 
current guidelines, CD diagnosis was made in the presence of Marsh ≥ 2 histology associated 
with both anti-tissue Transglutaminase (a-tTG) IgA > 7 U/ml and positive anti-endomysial 
(EMA) antibodies [11]. All subjects with positive serology but negative histology (Marsh 0 or 1) 
underwent further investigations for genetic susceptibility and were diagnosed as “potential” CD 
in the presence of HLA DQ2/DQ8. The main demographic, clinical, serological, endoscopic and 
histological features were recorded for all CD patients. All patients were investigated for the 
presence of Th1/Th17 and/or Th2-IMD at the time of CD diagnosis. The diagnosis of pre-
existent and new IMD was made by the evaluation of medical records with the confirmation of a 
specialist visit (i.e. rheumatologist, dermatologist, immunologist) and laboratory tests. The 
classification of Th1/Th17 and Th2-IMD was made in line with current guidance [13-15].
Information on the presence/absence of any allergic, atopic, or autoimmune disease preceding 
CD diagnosis was gathered at the time of the first consultation and during the study period each 
study participant underwent clinical examination and laboratory tests at least once a year. 
In particular, we assessed the clinical and biochemical presence of: vitiligo, allergic rhinitis, 
ankylosing spondylitis, Sjogren syndrome, multiple sclerosis, scleroderma, nephrotic syndrome, 
ulcerative colitis, psoriasis, polymyalgia rheumatica,  urticaria, IgA nephropathy, lichen planus, 
systemic lupus erythematosus, type 1 diabetes mellitus (or latent autoimmune diabetes in adults), 
Hashimoto’s thyroiditis, eczema, atopic dermatitis, primary sclerosing cholangitis, Crohn’s 
disease, allergic conjunctivitis, primary biliary cirrhosis, Grave’s disease, asthma, alopecia, 
rheumatoid arthritis and other allergies. Table 1 summarizes the main Th1-, Th17- and Th2-
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IMD. The search for Th1/Th17 and/or Th2-IMD was reassessed after starting GFD in a 5-years 
follow-up period.
Statistical analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS software v.15.0, 
Chicago IL, United States) for Windows. The descriptive statistics included determination of 
mean values and standard deviation (SD) of the continuous variables, and the percentages and 
proportions of the categorical variables. The chi-square (χ2) test was used to assess the 
comparison of categorical variables, while the Mann-Whitney U test was used for unpaired data. 
Analysis of variance (ANOVA) was performed with and without adjustment for covariates. The 
odd ratio (OR) for quantifying the statistical difference between the dichotomous variables was 
also calculated. All results were considered statistically significant when p value < 0.05.
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RESULTS
During the study period, 1255 CD patients referred to our Centre were enrolled (males/females 
258/997). At the time of CD diagnosis, mean age + SD was 28,1 + 15,7; mean a-tTG serum level 
was 98,7 + 108,2 U/mL; all patients were positive for EMA. Histological exam showed a Marsh 
1 grade in 64 patients (5%), Marsh 2 grade in 50 (4%), Marsh 3A in 171 (13.7%), Marsh 3B in 
311 (24.8%), and Marsh 3C in 659 (52.5%). Main patient characteristics and diagnostic results 
are reported in Table 2.
Data collected through medical history showed that 257 patients out of 1255 (20.5%) suffered 
from at least one immunological/allergic IMD before the diagnosis of CD. Of these, 150 (58.4%) 
suffered from Th1/Th17-mediated and 107 (41.6%) from Th2-mediated diseases (p=0.7). Table 
3 reports the prevalence of all IMD found in our population.
In the 5-years study period following CD diagnosis, 682 patients out of 1255 (54.3%) developed 
other immuno-mediated diseases regardless of whether they were following a strict GFD (mean 
a-tTG levels were 1,2 + 0,8 U/mL; negative EMA). Of these 682 patients, 391 (57.3%) 
developed a Th1/Th17-related disease, and 291 (42.7%) a Th2-mediated condition (p=0.8). Also 
in this case, Table 3 summarizes all results relating to the type of IMD present and their 
prevalence at the time of diagnosis and after GFD.
We compared the prevalence of immuno-mediated diseases pre- and post-CD diagnosis and 
found that there was no significant ‘switch’ from Th1/Th17-mediated to Th2-mediated response 
or vice versa (58.4% and 41.6%, respectively, pre-CD diagnosis; 57.3% and 42.7% post-CD 
diagnosis; p=0.9). The number of patients with either a Th1- or a Th2-mediated disease 
increased over time in the period following CD diagnosis (20.5% vs 54.3%; p<0.01; OR 1.9;95% 
C.I. 1.5-2.1). Of the 1255 participants in the study, 150 (12%) were affected by Th1/Th17-IMD 
at the time of CD diagnosis and 391 (31%) following CD diagnosis (p<0.01; OR 2.6); 107 
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(8.5%) showed a Th2-IMD at the time of CD diagnosis and 291 (23.3%) following CD diagnosis 
(p<0.01; OR 1.6; 95%C.I. 1.3-1.9). 
When we examined the prevalence of the most frequent CD-related IMD, we found that 
Hashimoto’s thyroiditis was present in 8.2% of patients at the time of CD diagnosis and in 24% 
of patients after CD diagnosis (p<0.01; OR 1.6, 95%C.I. 1.5-1.7); 0.7% of patients suffered from 
psoriasis before CD diagnosis while 2.7% developed it after CD diagnosis (p<0.01; OR 1.5; 
95%C.I. 1.3-1.8); type 1 diabetes mellitus was present in 1.8% of patients at the time of CD 
diagnosis and in only 0.2% after CD diagnosis (p<0.01; OR 0.08, 95%C.I. 0.01-0.4) (Table 3).
No correlation was found between the occurrence of autoimmune/allergic diseases and any of the 
following variables: age at the time of CD diagnosis, a-tTG serum levels at the time of diagnosis 
and at follow-up, Marsh grade and clinical symptoms (P = NS). Table 4 better clarifies these 
results.
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DISCUSSION
At present, the only treatment for CD is represented by gluten free diet (GFD). 
Numerous papers have explored the effects of GFD on the incidence and course of CD-
associated IMD, often reporting contradictory results. Most of these studies, however, supported 
the hypothesis of a protective effect of GFD with regard to the occurrence of CD-associated IMD 
[12].
Our study investigated the relationship between GFD and CD-associated IMD with a specific 
focus on the relative prevalence of Th1/Th17- and Th2-mediated diseases before and after the 
start of GFD. Our results suggest that we should re-examine the widely shared view that GFD is 
a magic bullet for the treatment of all pathological conditions associated with CD. Our study 
included a large population of patients suffering from CD (1255 in total), which strengthens our 
results and suggestions for practice. The present study confirms the outcomes firstly reported by 
Elli et al [30 – 31]. In particular, the Authors explored the rate of IMD in 1015 CD patients 
reporting a significantly elevated prevalence (23%) of IMD in CD. Interestingly, the occurrence 
of IMD was not influenced by sex, GFD compliance, and time of gluten exposure.
On the other hands, in a French multicentric study on adult and pediatric CD patients, Cosnes et al 
[26] retrospectively evaluated 927 coeliac patients. Of these, 178 (19.3%) developed one or several 
autoimmune diseases. The cumulative risk of autoimmune disease was 8.1% + 1% at age 15, and 
15.7% + 1.5% at age 30. The cumulative risk of subsequent autoimmune disease was lower in 
patients who followed a GFD than in those who did not (p<0.05). The incidence of autoimmune 
disease was 5.4/1000 patient-years in the case of adherence to a GFD vs 11.3/1000 patient-years in 
the case of non-adherence to the diet (p < 0.002). The Authors concluded that factors associated 
with an increased risk for immuno-mediated diseases were family history of autoimmunity (hazard 
ratio 2.36) and diagnosis of coeliac disease before 36 years of age (hazard ratio 2.65). In other 
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words, for Cosnes and colleagues GFD seemed to have a protective role, maybe by contributing to 
re-establishing the integrity of the intestinal barrier. The suggestion by Cosnes et al., however, 
contrasted with the results from another large Italian study by Ventura et al. [29] (carried out with a 
sample population of 909 coeliac patients) which concluded that a higher prevalence of other 
autoimmune disorders was associated with longer duration of exposure to gluten. 
Some studies exist which question the protective effect of GFD on the occurrence of CD-associated 
IMD. In 2005, Viljamaa et al [27] studied 703 CD patients: even though they found an increased 
risk of autoimmune disease in CD patients (prevalence of 21.8%), the Authors concluded that the 
duration of gluten exposure seemed not to be of crucial importance in the development of 
autoimmune diseases. A similar conclusion was reached by Sategna Guidetti et al. [37], who 
reported a prevalence of autoimmune disease in CD patients of about 30%. In our study, we did not 
find any correlation between the development of IMD and the age at the time of diagnosis. It seems 
to us that, once started, the “autoimmune waterfall”, cannot be stopped by GFD, thus leading to an 
increased risk of developing IMD. About this issue, a different conclusion was reached by Elli et al 
[30] reporting a quite protective effect of longstanding gluten exposure on the occurrence of IMD. 
In effect, the Authors found that the increment of 1 year in CD diagnosis corresponded to a lower 
risk of developing IMD (HR 0.30).
With regard to the CD-relat d IMD found in our study population, the most frequent were: 
Hashimoto’s thyroiditis (8.2% before vs 24% after CD diagnosis; p<0.01; OR 1.6 (IC:1.5-1.7)); 
psoriasis (0.7% before vs 2.7% after CD diagnosis; p<0.01; OR 1.5 (IC 1.3-1.8)); type 1 diabetes 
mellitus (1.8% before vs 0.2% after CD diagnosis; p<0.01; OR 0.08 (IC 0.01-0.4)). 
The association between CD and thyroid disorders is well known. In a study conducted by Hadithi 
et al. [38], 4.8% of Dutch patients with Hashimoto’s thyroiditis had CD, and 12% of patients with 
CD had Hashimoto’s thyroiditis. In a prospective study of 27 adult coeliac patients, Metso et al. 
[32] found that CD subjects had an elevated anti-TPO levels, which continued to increase despite 
GFD. Thyroid atrophy also progressed while on a GFD. The Authors suggested that GFD seemed 
Page 12 of 22
Ac
ce
pte
d M
an
us
cri
pt
12
not to prevent the progression of the autoimmune process in adults during a 1-year follow up. The 
observation by Metso et al. is in accordance with the results from our study: 24% of CD patients 
showed Hashimoto’s thyroiditis during the study period but only 8.2% of patients had presented 
thyroiditis before CD diagnosis (p<0.01; OR 1.6).
The association between psoriasis and CD remains unclear [39 – 40]. Ludvigsson et al. [41] found 
that CD was a risk factor for future psoriasis (hazard ratio 1.72). In our study population, 0.7% of 
patients suffered from psoriasis before CD diagnosis while 2.7% developed it during the post-CD 
diagnosis period (p<0.01; OR 1.5), confirming previous results. 
Several recent studies have showed a higher prevalence of Metabolic Syndrome (MS) and its 
components among subjects suffering from psoriasis (between 4.3 and 40%), compared to the 
general population. A recent systematic and meta-analytical review of several observation studies 
described an OR of 2.26 for MS in subjects with psoriasis [42]. Psoriasis appears more frequent in 
obese subjects [43]. In a recent publication, our team [44] demonstrated a high risk for development 
of MS in CD patients on GFD. This finding could explain an important common pathogenetic 
mechanism linking CD and psoriasis. 
The association between CD and type 1 diabetes mellitus is well established. In the majority of 
cases (more than 90%), the diagnosis of diabetes precedes that of CD, as confirmed by Greco et al. 
[45]. However, some studies have reported that diabetes onset can frequently occur in patients 
already diagnosed with CD. Valerio et al. [46], for example, demonstrated that diagnosis of CD 
prior to onset of diabetes denotes a subgroup of patients with a more severe clinical presentation of 
diabetes and higher prevalence of multiple autoimmune diseases, suggesting that GFD does not help 
to prevent other autoimmune disorders which have already been triggered. In our study population 
diabetes was present in 1.8% of patients before CD diagnosis, but after starting GFD only 0.2% 
presented diabetes (p<0.01; OR 0.08). This result could be explained by the fact that ours is an adult 
population. In effect, type 1 diabetes mellitus usually presents in adolescent and young adults, 
except for latent autoimmune diabetes of the adults (LADA) which affected 2 patients in the study. 
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In our paper we consider also the Th2-mediated diseases, such as allergic diseases. No statistically 
significant differences were found between the percentage of Th2-predominant disorders before and 
after CD diagnosis (41.6% and 42.7%, respectively, P = NS), although the absolute number of 
patients affected by a Th2 disease increased during GFD (107 vs 291, p < 0.01). Therefore, it seems 
that the coeliac population is also particularly susceptible to allergic diseases, even after starting 
GFD. 
However, there were some limitations to our study. In this paper, we used a-tTg as a surrogate 
marker for GFD adherence at 5-year follow-up. This method used to assess adherence has 
limitations, and may not accurately reflect true adherence/mucosal healing [47], even though 
current guidelines suggest to perform upper endoscopy with intestinal biopsies in cases with lack of 
clinical response or relapse of symptoms despite a GFD [2]. Furthermore, we had no data on IMD 
occurrence in non-CD patients. However, a previous paper by Elli and colleagues [30], comparing 
the prevalence of IMD in 1015 CD patients with those of a registry population (848.606 subjects), 
underlined a significantly high percentage of IMD in CD patients respect to the controls (23% vs 
0.4%); these results confirm the specific role of CD in predisposing patients to other IMD.
In summary, CD has been associated with different IMD and allergic diseases, especially 
Hashimoto’s thyroiditis, type 1 diabetes mellitus and psoriasis. The prevalence of immune-mediated
diseases at the time of CD diagnosis is high and it seems to increase in the follow-up period. GFD 
does not influence (and in particular, it does not reduce) the prevalence, the occurrence or the 
Th1/Th17-Th2 nature of immune-mediated diseases in CD. Our results therefore suggest we should 
re-examine the widely shared view that GFD is a sort of magic bullet for all pathological conditions 
associated with CD.
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Table 1. Classification of main Th1/Th17 and Th-2 mediated disorders.
Th1/Th17-mediated diseases Th2-mediated diseases
Coeliac disease IgE related-allergies
Vitiligo Sjogren syndrome
Ankylosing spondylitis Allergic conjunctivitis
Multiple sclerosis Atopic dermatitis
Nephrotic syndrome Grave’s disease
Crohn’s disease Ulcerative colitis
Psoriasis Asthma
Polymyalgia rheumatic Urticaria
Alope ia Eczema
IgA nephropathy Scleroderma
type 1 Diabetes Mellitus Systemic lupus erythematosus
Hashimoto’s thyroiditis Allergic rhinitis
Rheumatoid arthritis Lichen planus
Primary biliary cirrhosis Other allergies
Primary sclerosing cholangitis
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Table 2. Main patient characteristics and diagnostic results of 1255 coeliac patients.
Number (%)
Male 258 (20.6)
Female 997 (79.4)
Demographic data
Mean age ± SD 28.1 ± 15.7
Classical CD 454 (36.2)
Non Classical CD 627 (49.9)
Asymptomatic CD 110 (8.7)
Symptoms (in 
accordance with 
Oslo) [11]
Potential CD 64 (5)
Down Syndrome 8 (0.6)
Risk factors for CD
Familial history of CD 406 (32.3)
a-tTG (U/ml) 98.7 ± 108.2
Laboratory
EMA positive 100% 
Marsh 1 64 (5)
Marsh 2 50 (4)
Marsh 3A 171 (13.7)
Marsh 3B 311 (24.8)
Histology
Marsh 3C 659 (52.5)
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 Table 3. Main immune-mediated diseases presenting before (Pre) and after (Post) CD diagnosis. 
They were divided into Th1/Th17 and Th2-mediated conditions; p is expressed only in case of 
statistically significant results.
Th1/Th17-Th2 Disease
Pre *
n° (%)
Post **
n°(%)
p OR
Vitiligo 4 (0.3) 7 (0.5) 0.3
Ankylosing spondylitis - 4 (0.3) 0.1
Multiple sclerosis - 1 (0.1) 0.9
Nephrotic syndrome - 3 (0.2) 0.3
Crohn’s disease - 7 (0.5) 0.09
Psoriasis 9 (0.7) 35 (2.8) 0.01 1.5
Polymyalgia rheumatic 1 (0.1) 3 (0.2) 0.3
Alopecia 7 (0.5) 8 (0.6) 0.7
IgA nephropathy - 1 (0.1) 0.9
type 1 dabetes mellitus 22 (1.8) 2 (0.2) <0.01 0.08
Hashimoto’s thyroiditis 103 (8.2) 301 (24) <0.01 1.6
Rheumatoid arthritis 4 (0.3) 15 (1.2) 0.09
Primary biliary cirrhosis - 2 (0.2) 0.5
Th1/Th17 
mediated
conditions
Primary sclerosing cholangitis - 2 (0.2) 0.5
Ulcerative colitis - 15 (1.2) 0.08
Allergic conjunctivitis 1 (0.1) 11 (0.9) 0.1
Atopic dermatitis 8 (0.6) 26 (2.1) 0.08
Grave’s disease 4 (0.3) 20 (1.6) 0.1
Asthma 33 (2.7) 47 (3.8) 0.1
Urticaria 8 (0.6) 24 (1.9) 0.2
Eczema 1 (0.1) 11 (0.9) 0.3
Scleroderma - 10 (0.8) 0.1
Systemic lupus erythematosus 1 (0.1) 13 (1) 0.09
Allergic rhinitis 35 (2.8) 53 (4.2) 0.08
Lichen planus - 11 (0.9) 0.1
Sjogren syndrome - 13 (1) 0.09
Th2 mediated 
conditions
Other allergies 16 (1.3) 37 (2.9) 0.01
257 (20.5) 682 (54.3) <0.01 1.9
* All IMD diagnosed before CD diagnosis
** All new diagnoses of IMD found after CD diagnosis during the follow-up
Page 22 of 22
Ac
ce
pte
d M
an
us
cri
pt
22
Table 4. Correlation between the occurrence of IMD and: age at the time of CD diagnosis, a-tTG 
serum levels at the time of diagnosis and at follow-up, clinical symptoms, Marsh grade.
IMD No IMD p
Age (years) at time of CD diagnosis
 (mean + SD)
29.93 + 16.66 30.93 + 14.03 0.2
tTG IgA levels at time of CD diagnosis
(U/mL)
(mean + SD)
89.73 + 90.95 93.84 + 85.88 0.4
tTG IgA levels at follow-up
(U/mL)
(mean + SD)
1.2 + 0.9 1.3 + 1.2 0.09
Classical CD 
(%)
56.4% 43.6% 0.1
Non Classical CD 
(%)
55.9% 44.1% 0.2
Symptoms (in 
accordance with 
Oslo) [11]
Asymptomatic CD 
(%)
56.3% 43.7% 0.1
Marsh 1 (%) 5.1% 5% 0.9
Marsh 2 (%) 3.8% 4.2% 0.7Marsh Grade
Marsh 3 (%) 91.1% 90.8% 0.7
